Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Vor Biopharma has raised $75.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2026.
Vor Biopharma's investors include RA Capital Management, Qiming Venture Partners, TCG Crossover, OUP (Osage University Partners), Frazier Life Sciences.
Vor Biopharma is headquartered in Cambridge, United States.
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Vor Biopharma is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vor Biopharma — Funding & Investors." VCBacked, March 27, 2026, https://www.vcbacked.co/company/vor-biopharma. Accessed August 14, 2026.
VCBacked. (2026). Vor Biopharma — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/vor-biopharma
{{cite web |title=Vor Biopharma — Funding & Investors |url=https://www.vcbacked.co/company/vor-biopharma |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated